Stay updated on Biomarker Response to Immunotherapy in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Biomarker Response to Immunotherapy in NSCLC Clinical Trial page.

Latest updates to the Biomarker Response to Immunotherapy in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a Phase II clinical trial for immunotherapy drugs ipilimumab and nivolumab, and the addition of a new revision number and collaborators.SummaryDifference44%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check45 days agoChange DetectedThe page has updated the names of key individuals and the dates associated with updates, replacing Mark Awad, MD with Biagio Ricciuti and changing the last update dates to March 2025.SummaryDifference1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Biomarker Response to Immunotherapy in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Response to Immunotherapy in NSCLC Clinical Trial page.